PPARγ agonists promote the resolution of myelofibrosis in preclinical models.


Journal

The Journal of clinical investigation
ISSN: 1558-8238
Titre abrégé: J Clin Invest
Pays: United States
ID NLM: 7802877

Informations de publication

Date de publication:
01 06 2021
Historique:
received: 23 01 2020
accepted: 22 04 2021
pubmed: 30 4 2021
medline: 5 10 2021
entrez: 29 4 2021
Statut: ppublish

Résumé

Myelofibrosis (MF) is a non-BCR-ABL myeloproliferative neoplasm associated with poor outcomes. Current treatment has little effect on the natural history of the disease. MF results from complex interactions between (a) the malignant clone, (b) an inflammatory context, and (c) remodeling of the bone marrow (BM) microenvironment. Each of these points is a potential target of PPARγ activation. Here, we demonstrated the therapeutic potential of PPARγ agonists in resolving MF in 3 mouse models. We showed that PPARγ agonists reduce myeloproliferation, modulate inflammation, and protect the BM stroma in vitro and ex vivo. Activation of PPARγ constitutes a relevant therapeutic target in MF, and our data support the possibility of using PPARγ agonists in clinical practice.

Identifiants

pubmed: 33914703
pii: 136713
doi: 10.1172/JCI136713
pmc: PMC8159700
doi:
pii:

Substances chimiques

Antineoplastic Agents 0
Neoplasm Proteins 0
PPAR gamma 0
Pparg protein, mouse 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Références

Front Cell Dev Biol. 2020 Jul 08;8:605
pubmed: 32733895
N Engl J Med. 2012 Mar 1;366(9):799-807
pubmed: 22375971
J Clin Invest. 2008 May;118(5):1765-75
pubmed: 18431514
J Hematol Oncol. 2017 Sep 29;10(1):156
pubmed: 28962635
J Physiol Pharmacol. 2011 Jun;62(3):347-56
pubmed: 21893696
J Cell Physiol. 1999 Oct;181(1):153-9
pubmed: 10457363
Blood. 2006 Jun 15;107(12):4589-96
pubmed: 16484590
Br J Haematol. 2015 Jul;170(1):29-39
pubmed: 25824940
FEBS Lett. 2006 Nov 27;580(27):6289-94
pubmed: 17097645
Clin Lymphoma Myeloma Leuk. 2015 Dec;15(12):785-9
pubmed: 26422250
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
N Engl J Med. 2012 Mar 1;366(9):787-98
pubmed: 22375970
Leukemia. 2008 Jan;22(1):14-22
pubmed: 17882280
Biochem Biophys Res Commun. 2008 Sep 19;374(2):231-6
pubmed: 18627765
FASEB J. 2009 Sep;23(9):2968-77
pubmed: 19395477
Biochem J. 2017 Apr 24;474(9):1531-1546
pubmed: 28100650
Blood. 2017 Feb 9;129(6):680-692
pubmed: 28028026
Blood. 2014 May 29;123(22):e123-33
pubmed: 24740812
Blood. 1990 Apr 1;75(7):1540-8
pubmed: 2317561
Hepatology. 2015 Nov;62(5):1551-62
pubmed: 26199136
Stem Cell Reports. 2017 May 9;8(5):1242-1255
pubmed: 28416286
J Hypertens. 2010 Jul;28(7):1488-97
pubmed: 20410836
Rheumatology (Oxford). 2012 Nov;51(11):1942-52
pubmed: 22829690
Br J Haematol. 1991 Jan;77(1):80-6
pubmed: 1998600
Blood. 2016 Mar 10;127(10):1317-24
pubmed: 26608331
Eur Rev Med Pharmacol Sci. 2018 Dec;22(24):8839-8848
pubmed: 30575926
Ann Oncol. 2015 Sep;26 Suppl 5:v85-99
pubmed: 26242182
Mediators Inflamm. 2015;2015:670580
pubmed: 26525644
Blood. 2015 May 21;125(21):3347-50; quiz 3364
pubmed: 25784679
Transl Med UniSa. 2014 Feb 04;8:53-64
pubmed: 24778998
Am J Hematol. 2016 Feb;91(2):211-9
pubmed: 26573090
Blood Adv. 2019 Jun 11;3(11):1729-1737
pubmed: 31175128
Exp Hematol. 2007 May;35(5):702-11
pubmed: 17577920
Biol Blood Marrow Transplant. 2016 Apr;22(4):644-650
pubmed: 26708839
Cell. 2005 Dec 16;123(6):993-9
pubmed: 16360030
Nat Med. 2018 Mar;24(3):360-367
pubmed: 29377004
Diabetes. 2004 May;53(5):1243-52
pubmed: 15111493
Am J Respir Cell Mol Biol. 2011 Jul;45(1):111-9
pubmed: 20870897
Curr Opin Rheumatol. 2010 Nov;22(6):671-6
pubmed: 20693905
Nat Rev Immunol. 2002 Oct;2(10):748-59
pubmed: 12360213
Mediators Inflamm. 2015;2015:606819
pubmed: 26538830
PPAR Res. 2015;2015:549691
pubmed: 26713087
Nature. 1998 Jan 1;391(6662):79-82
pubmed: 9422508
Am J Physiol Gastrointest Liver Physiol. 2006 Nov;291(5):G902-11
pubmed: 16798724
Nature. 2015 Sep 17;525(7569):380-3
pubmed: 26331539
Curr Protoc Pharmacol. 2017 Jun 22;77:14.40.1-14.40.19
pubmed: 28640953
Blood. 2018 May 31;131(22):2426-2435
pubmed: 29650801
Nature. 1998 Jan 1;391(6662):82-6
pubmed: 9422509
J Cell Physiol. 2016 Mar;231(3):587-96
pubmed: 26206105
Blood. 2002 Nov 15;100(10):3495-503
pubmed: 12393681
Ultrastruct Pathol. 2018 Nov-Dec;42(6):498-507
pubmed: 30582392
Neurol Res. 2010 Oct;32(8):852-9
pubmed: 20350367
Blood. 2013 Aug 22;122(8):1464-77
pubmed: 23863895
JCI Insight. 2017 Apr 6;2(7):e90932
pubmed: 28405618
Clin Pharmacol Ther. 2007 Sep;82(3):275-81
pubmed: 17361126
Cell. 1998 Dec 11;95(6):749-58
pubmed: 9865693
Therap Adv Gastroenterol. 2011 Jul;4(4):237-48
pubmed: 21765868
Cancer. 2017 May 15;123(10):1791-1799
pubmed: 28026860
Blood. 2012 Apr 12;119(15):3539-49
pubmed: 22144185
Int J Mol Sci. 2017 Oct 17;18(10):
pubmed: 29039786
Expert Rev Hematol. 2016 May;9(5):489-96
pubmed: 26891375
Blood. 2004 Sep 1;104(5):1361-8
pubmed: 15130939
Nat Commun. 2012;3:1300
pubmed: 23250430
N Engl J Med. 2000 Apr 27;342(17):1255-65
pubmed: 10781623
Open Rheumatol J. 2012;6:103-15
pubmed: 22802908
Stem Cell Investig. 2016 Feb 26;3:5
pubmed: 27358897
Br J Pharmacol. 2003 Sep;140(2):366-76
pubmed: 12970094
FASEB J. 1999 Oct;13(13):1774-86
pubmed: 10506580
Growth Factors. 2011 Oct;29(5):196-202
pubmed: 21740331
Haematologica. 2018 Mar;103(3):438-446
pubmed: 29217781
Nat Commun. 2020 Sep 28;11(1):4886
pubmed: 32985500
N Engl J Med. 2013 Dec 19;369(25):2379-90
pubmed: 24325356
PPAR Res. 2015;2015:124624
pubmed: 26064084
Blood. 1997 Dec 1;90(11):4369-83
pubmed: 9373248
Cell Stem Cell. 2013 Sep 5;13(3):285-99
pubmed: 23850243
Mol Pharmacol. 2006 Jul;70(1):415-25
pubmed: 16611854
J Clin Oncol. 2012 Aug 20;30(24):2981-7
pubmed: 22826273
Biochem Biophys Res Commun. 2006 Nov 17;350(2):385-91
pubmed: 17010940
Leukemia. 2018 Nov;32(11):2399-2411
pubmed: 29749399

Auteurs

Juliette Lambert (J)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.
Department of Hematology and Oncology, Centre Hospitalier de Versailles, Le Chesnay, France.
Opale Carnot Institute, Paris, France.

Joseph Saliba (J)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.

Carolina Calderon (C)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.
Opale Carnot Institute, Paris, France.

Karine Sii-Felice (K)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.

Mohammad Salma (M)

Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.

Valérie Edmond (V)

INSERM, UMR1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Jean-Claude Alvarez (JC)

Département de Pharmacologie-Toxicologie, Hôpitaux Universitaires Paris Ile-de-France Ouest, AP-HP, Hôpital Raymond-Poincaré, FHU Sepsis, Garches, France.
MasSpecLab, Plateforme de spectrométrie de masse, INSERM U-1173, Université Paris-Saclay (Versailles Saint-Quentin-en-Yvelines), UFR des sciences de la santé, Montigny-le-Bretonneux, France.

Marc Delord (M)

Recherche Clinique, Centre Hospitalier de Versailles, Le Chesnay, France.

Caroline Marty (C)

INSERM, UMR1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Isabelle Plo (I)

INSERM, UMR1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Jean-Jacques Kiladjian (JJ)

Opale Carnot Institute, Paris, France.
Université de Paris, AP-HP, Hôpital Saint-Louis, Centre d'Investigations Cliniques CIC 1427, INSERM, Paris, France.

Eric Soler (E)

Institut de Génétique Moléculaire de Montpellier, University of Montpellier, CNRS, Montpellier, France.
Université de Paris, Laboratory of Excellence GR-Ex, Paris, France.

William Vainchenker (W)

INSERM, UMR1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Jean-Luc Villeval (JL)

INSERM, UMR1287, Université Paris-Saclay, Gustave Roussy, Villejuif, France.

Philippe Rousselot (P)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.
Department of Hematology and Oncology, Centre Hospitalier de Versailles, Le Chesnay, France.
Opale Carnot Institute, Paris, France.
Université Paris-Saclay (Versailles Saint-Quentin-en-Yvelines), UFR des sciences de la santé, Montigny-le-Bretonneux, France.

Stéphane Prost (S)

Division of Innovative Therapies, CEA/DRF/François Jacob Biology Institute, UMR1184 IMVA-HB/IDMIT, Université Paris-Saclay, Fontenay-aux-Roses, France.
Opale Carnot Institute, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH